Overview
USANA preliminary Q3 net sales of $214 mln missed analyst expectations
Preliminary adjusted EPS for Q3 was negative, reflecting sales and productivity challenges
Company faced high effective tax rate impacting Q3 profitability
Outlook
USANA expects full-year sales at the lower end of previous guidance
USANA anticipates future lower tax rate due to cost alignment efforts
Result Drivers
COMPENSATION PLAN TRANSITION - Co attributes softer sales and productivity to the rollout of an enhanced Brand Partner compensation plan
HIYA SALES - Hiya's lower than anticipated customer acquisition rates led to softer sales in a seasonally strong quarter
HIGH TAX RATE - Co faced a significant increase in the effective income tax rate, impacting Q3 profitability
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Prelim Q3 Sales | Miss | $214 mln | $224.10 mln (1 Analyst) |
Prelim Q3 EPS | -$0.36 |
Analyst Coverage
Wall Street's median 12-month price target for USANA Health Sciences Inc is $61.00, about 56.5% above its October 8 closing price of $26.51
The stock recently traded at 8 times the next 12-month earnings vs. a P/E of 10 three months ago
Press Release: ID:nBw72nDPHa
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)